The effect of zanamivir treatment on the early immune response to influenza vaccination
Identifieur interne : 001857 ( Main/Exploration ); précédent : 001856; suivant : 001858The effect of zanamivir treatment on the early immune response to influenza vaccination
Auteurs : Rebecca J. Cox [Norvège] ; Eva Mykkeltvedt [Norvège] ; H Kon Sjursen [Norvège] ; Lars R. Haaheim [Norvège]Source :
- Vaccine [ 0264-410X ] ; 2001.
English descriptors
- KwdEn :
- Teeft :
- Antibody, Antibody response, Antibody titres, Antigenic, Bergen, Days post vaccination, Early humoral, Haaheim, Haemagglutination inhibition, High activity, Higher numbers, Inhaled zanamivir, Lower numbers, Parenteral vaccination, Placebo, Placebo group, Placebo groups, Prophylaxis, Serum antibody, Side reactions, Time course, Titre, Vaccination, Vaccine, Vaccine strains, Virus infections, Zanamivir, Zanamivir group, Zanamivir placebo, Zanamivir placebo zanamivir placebo zanamivir placebo, Zanamivir treatment.
Abstract
Abstract: Zanamivir is licensed for influenza treatment, but may also play a role in prophylaxis either alone or in combination with vaccine in epidemic periods. We conducted a double blind placebo controlled trial to investigate the effect of zanamivir treatment on the humoral immune response to influenza vaccine. Forty young healthy volunteers were vaccinated with licensed trivalent influenza vaccine and received 20 mg zanamivir (24 subjects) or placebo (16 subjects) daily for a period of 14 days. No significant differences were observed in the magnitude or the time course of the antibody response to the influenza H3N2 and B strains between the two groups, in contrast the placebo group responded with higher antibody titres to the H1N1. Our results suggest that during an influenza epidemic, volunteers would only need to continue zanamivir treatment for the initial 12 days after vaccination whilst the vaccine induced protective antibody response developed.
Url:
DOI: 10.1016/S0264-410X(01)00219-5
Affiliations:
Links toward previous steps (curation, corpus...)
- to stream Istex, to step Corpus: 001297
- to stream Istex, to step Curation: 001297
- to stream Istex, to step Checkpoint: 000684
- to stream Main, to step Merge: 001897
- to stream Main, to step Curation: 001857
Le document en format XML
<record><TEI wicri:istexFullTextTei="biblStruct"><teiHeader><fileDesc><titleStmt><title xml:lang="en">The effect of zanamivir treatment on the early immune response to influenza vaccination</title><author><name sortKey="Cox, Rebecca J" sort="Cox, Rebecca J" uniqKey="Cox R" first="Rebecca J" last="Cox">Rebecca J. Cox</name></author><author><name sortKey="Mykkeltvedt, Eva" sort="Mykkeltvedt, Eva" uniqKey="Mykkeltvedt E" first="Eva" last="Mykkeltvedt">Eva Mykkeltvedt</name></author><author><name sortKey="Sjursen, H Kon" sort="Sjursen, H Kon" uniqKey="Sjursen H" first="H Kon" last="Sjursen">H Kon Sjursen</name></author><author><name sortKey="Haaheim, Lars R" sort="Haaheim, Lars R" uniqKey="Haaheim L" first="Lars R" last="Haaheim">Lars R. Haaheim</name></author></titleStmt><publicationStmt><idno type="wicri:source">ISTEX</idno><idno type="RBID">ISTEX:3BF6595A812992732B475ECD41E3BA87389A02E6</idno><date when="2001" year="2001">2001</date><idno type="doi">10.1016/S0264-410X(01)00219-5</idno><idno type="url">https://api.istex.fr/ark:/67375/6H6-5N9K0SXX-F/fulltext.pdf</idno><idno type="wicri:Area/Istex/Corpus">001297</idno><idno type="wicri:explorRef" wicri:stream="Istex" wicri:step="Corpus" wicri:corpus="ISTEX">001297</idno><idno type="wicri:Area/Istex/Curation">001297</idno><idno type="wicri:Area/Istex/Checkpoint">000684</idno><idno type="wicri:explorRef" wicri:stream="Istex" wicri:step="Checkpoint">000684</idno><idno type="wicri:doubleKey">0264-410X:2001:Cox R:the:effect:of</idno><idno type="wicri:Area/Main/Merge">001897</idno><idno type="wicri:Area/Main/Curation">001857</idno><idno type="wicri:Area/Main/Exploration">001857</idno></publicationStmt><sourceDesc><biblStruct><analytic><title level="a" type="main" xml:lang="en">The effect of zanamivir treatment on the early immune response to influenza vaccination</title><author><name sortKey="Cox, Rebecca J" sort="Cox, Rebecca J" uniqKey="Cox R" first="Rebecca J" last="Cox">Rebecca J. Cox</name><affiliation wicri:level="1"><country wicri:rule="url">Norvège</country></affiliation><affiliation wicri:level="1"><country xml:lang="fr">Norvège</country><wicri:regionArea>Department of Molecular Biology, University of Bergen, N-5020 Bergen</wicri:regionArea><wicri:noRegion>N-5020 Bergen</wicri:noRegion></affiliation></author><author><name sortKey="Mykkeltvedt, Eva" sort="Mykkeltvedt, Eva" uniqKey="Mykkeltvedt E" first="Eva" last="Mykkeltvedt">Eva Mykkeltvedt</name><affiliation wicri:level="1"><country xml:lang="fr">Norvège</country><wicri:regionArea>Department of Molecular Biology, University of Bergen, N-5020 Bergen</wicri:regionArea><wicri:noRegion>N-5020 Bergen</wicri:noRegion></affiliation></author><author><name sortKey="Sjursen, H Kon" sort="Sjursen, H Kon" uniqKey="Sjursen H" first="H Kon" last="Sjursen">H Kon Sjursen</name><affiliation wicri:level="1"><country xml:lang="fr">Norvège</country><wicri:regionArea>Department of Infectious Diseases, Haukeland Hospital, University of Bergen, N-5020 Bergen</wicri:regionArea><wicri:noRegion>N-5020 Bergen</wicri:noRegion></affiliation></author><author><name sortKey="Haaheim, Lars R" sort="Haaheim, Lars R" uniqKey="Haaheim L" first="Lars R" last="Haaheim">Lars R. Haaheim</name><affiliation wicri:level="1"><country xml:lang="fr">Norvège</country><wicri:regionArea>Department of Microbiology and Immunology, University of Bergen, N-5020 Bergen</wicri:regionArea><wicri:noRegion>N-5020 Bergen</wicri:noRegion></affiliation></author></analytic><monogr></monogr><series><title level="j">Vaccine</title><title level="j" type="abbrev">JVAC</title><idno type="ISSN">0264-410X</idno><imprint><publisher>ELSEVIER</publisher><date type="published" when="2001">2001</date><biblScope unit="volume">19</biblScope><biblScope unit="issue">32</biblScope><biblScope unit="page" from="4743">4743</biblScope><biblScope unit="page" to="4749">4749</biblScope></imprint><idno type="ISSN">0264-410X</idno></series></biblStruct></sourceDesc><seriesStmt><idno type="ISSN">0264-410X</idno></seriesStmt></fileDesc><profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Antibody</term><term>Influenza vaccine</term><term>Zanamivir</term></keywords><keywords scheme="Teeft" xml:lang="en"><term>Antibody</term><term>Antibody response</term><term>Antibody titres</term><term>Antigenic</term><term>Bergen</term><term>Days post vaccination</term><term>Early humoral</term><term>Haaheim</term><term>Haemagglutination inhibition</term><term>High activity</term><term>Higher numbers</term><term>Inhaled zanamivir</term><term>Lower numbers</term><term>Parenteral vaccination</term><term>Placebo</term><term>Placebo group</term><term>Placebo groups</term><term>Prophylaxis</term><term>Serum antibody</term><term>Side reactions</term><term>Time course</term><term>Titre</term><term>Vaccination</term><term>Vaccine</term><term>Vaccine strains</term><term>Virus infections</term><term>Zanamivir</term><term>Zanamivir group</term><term>Zanamivir placebo</term><term>Zanamivir placebo zanamivir placebo zanamivir placebo</term><term>Zanamivir treatment</term></keywords></textClass><langUsage><language ident="en">en</language></langUsage></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">Abstract: Zanamivir is licensed for influenza treatment, but may also play a role in prophylaxis either alone or in combination with vaccine in epidemic periods. We conducted a double blind placebo controlled trial to investigate the effect of zanamivir treatment on the humoral immune response to influenza vaccine. Forty young healthy volunteers were vaccinated with licensed trivalent influenza vaccine and received 20 mg zanamivir (24 subjects) or placebo (16 subjects) daily for a period of 14 days. No significant differences were observed in the magnitude or the time course of the antibody response to the influenza H3N2 and B strains between the two groups, in contrast the placebo group responded with higher antibody titres to the H1N1. Our results suggest that during an influenza epidemic, volunteers would only need to continue zanamivir treatment for the initial 12 days after vaccination whilst the vaccine induced protective antibody response developed.</div></front></TEI><affiliations><list><country><li>Norvège</li></country></list><tree><country name="Norvège"><noRegion><name sortKey="Cox, Rebecca J" sort="Cox, Rebecca J" uniqKey="Cox R" first="Rebecca J" last="Cox">Rebecca J. Cox</name></noRegion><name sortKey="Cox, Rebecca J" sort="Cox, Rebecca J" uniqKey="Cox R" first="Rebecca J" last="Cox">Rebecca J. Cox</name><name sortKey="Haaheim, Lars R" sort="Haaheim, Lars R" uniqKey="Haaheim L" first="Lars R" last="Haaheim">Lars R. Haaheim</name><name sortKey="Mykkeltvedt, Eva" sort="Mykkeltvedt, Eva" uniqKey="Mykkeltvedt E" first="Eva" last="Mykkeltvedt">Eva Mykkeltvedt</name><name sortKey="Sjursen, H Kon" sort="Sjursen, H Kon" uniqKey="Sjursen H" first="H Kon" last="Sjursen">H Kon Sjursen</name></country></tree></affiliations></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Sante/explor/H2N2V1/Data/Main/Exploration
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 001857 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd -nk 001857 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Sante
|area= H2N2V1
|flux= Main
|étape= Exploration
|type= RBID
|clé= ISTEX:3BF6595A812992732B475ECD41E3BA87389A02E6
|texte= The effect of zanamivir treatment on the early immune response to influenza vaccination
}}
| This area was generated with Dilib version V0.6.33. |  |